Cargando…
Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardio...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509820/ https://www.ncbi.nlm.nih.gov/pubmed/34640348 http://dx.doi.org/10.3390/jcm10194332 |
_version_ | 1784582436845256704 |
---|---|
author | Jang, Gyeong-Won Lee, Jung Myung Choi, Seung Woo Kim, Joan Lee, Young Shin Kim, Hyung Oh Chung, Hyemoon Woo, Jong Shin Kim, Jin Bae Kim, Woo-Shik Kim, Weon |
author_facet | Jang, Gyeong-Won Lee, Jung Myung Choi, Seung Woo Kim, Joan Lee, Young Shin Kim, Hyung Oh Chung, Hyemoon Woo, Jong Shin Kim, Jin Bae Kim, Woo-Shik Kim, Weon |
author_sort | Jang, Gyeong-Won |
collection | PubMed |
description | This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardiovascular disease were registered and randomly assigned to either an NOAC group (dabigatran or rivaroxaban) or the warfarin group. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function were taken using Endo-PAT2000. Carotid intima–media thickness (IMT) was measured at baseline, 12 months, and 24 months, and several biomarkers were also analyzed. For the primary end point, the reactive hyperemia index (RHI) for the NOAC group was 1.5 ± 0.4 and that for the warfarin group was 1.6 ± 0.5. The left and right carotid IMT was 0.7 mm in the NOAC groups and 0.8 mm in the warfarin group. At 12 months, RHI was 1.6 ± 0.3 for the dabigatran group, 1.6 ± 0.5 for the rivaroxaban group, and 1.6 ± 0.3 for the warfarin group. The three groups did not differ statistically with respect to change in left and right carotid IMT at 12 and 24 months, respectively. The biomarkers for endothelial function and atherosclerosis were not significantly different. There was a trend of reduced P-selectin levels in the NOAC group compared to the warfarin group. In patients with AF, there were no significant differences in the prevention of endothelial dysfunction and atherosclerosis progression between the NOAC and warfarin groups. |
format | Online Article Text |
id | pubmed-8509820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85098202021-10-13 Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation Jang, Gyeong-Won Lee, Jung Myung Choi, Seung Woo Kim, Joan Lee, Young Shin Kim, Hyung Oh Chung, Hyemoon Woo, Jong Shin Kim, Jin Bae Kim, Woo-Shik Kim, Weon J Clin Med Article This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardiovascular disease were registered and randomly assigned to either an NOAC group (dabigatran or rivaroxaban) or the warfarin group. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function were taken using Endo-PAT2000. Carotid intima–media thickness (IMT) was measured at baseline, 12 months, and 24 months, and several biomarkers were also analyzed. For the primary end point, the reactive hyperemia index (RHI) for the NOAC group was 1.5 ± 0.4 and that for the warfarin group was 1.6 ± 0.5. The left and right carotid IMT was 0.7 mm in the NOAC groups and 0.8 mm in the warfarin group. At 12 months, RHI was 1.6 ± 0.3 for the dabigatran group, 1.6 ± 0.5 for the rivaroxaban group, and 1.6 ± 0.3 for the warfarin group. The three groups did not differ statistically with respect to change in left and right carotid IMT at 12 and 24 months, respectively. The biomarkers for endothelial function and atherosclerosis were not significantly different. There was a trend of reduced P-selectin levels in the NOAC group compared to the warfarin group. In patients with AF, there were no significant differences in the prevention of endothelial dysfunction and atherosclerosis progression between the NOAC and warfarin groups. MDPI 2021-09-23 /pmc/articles/PMC8509820/ /pubmed/34640348 http://dx.doi.org/10.3390/jcm10194332 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jang, Gyeong-Won Lee, Jung Myung Choi, Seung Woo Kim, Joan Lee, Young Shin Kim, Hyung Oh Chung, Hyemoon Woo, Jong Shin Kim, Jin Bae Kim, Woo-Shik Kim, Weon Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title | Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title_full | Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title_fullStr | Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title_full_unstemmed | Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title_short | Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation |
title_sort | vascular protective effects of new oral anticoagulants in patients with atrial fibrillation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509820/ https://www.ncbi.nlm.nih.gov/pubmed/34640348 http://dx.doi.org/10.3390/jcm10194332 |
work_keys_str_mv | AT janggyeongwon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT leejungmyung vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT choiseungwoo vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT kimjoan vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT leeyoungshin vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT kimhyungoh vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT chunghyemoon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT woojongshin vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT kimjinbae vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT kimwooshik vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation AT kimweon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation |